Ontology highlight
ABSTRACT:
SUBMITTER: van Andel L
PROVIDER: S-EPMC5754411 | biostudies-literature | 2018 Jan
REPOSITORIES: biostudies-literature
van Andel L L Rosing H H Zhang Z Z Hughes L L Kansra V V Sanghvi M M Tibben M M MM Gebretensae A A Schellens J H M JHM Beijnen J H JH
Cancer chemotherapy and pharmacology 20171017 1
<h4>Introduction</h4>Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The pivotal phase III clinical trial has shown improved progression-free survival in patients receiving niraparib compared with those receiving ...[more]